Arcus Biosciences, Inc.
RCUS
$28.74
$0.020.07%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.00M | 17.00M | 33.00M | 26.00M | 160.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.00M | 17.00M | 33.00M | 26.00M | 160.00M |
| Cost of Revenue | 113.00M | 122.00M | 121.00M | 141.00M | 139.00M |
| Gross Profit | -72.00M | -105.00M | -88.00M | -115.00M | 21.00M |
| SG&A Expenses | 24.00M | 29.00M | 26.00M | 27.00M | 29.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.00M | 151.00M | 147.00M | 168.00M | 168.00M |
| Operating Income | -96.00M | -134.00M | -114.00M | -142.00M | -8.00M |
| Income Before Tax | -91.00M | -128.00M | -106.00M | -135.00M | 0.00 |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.00M | -128.00M | -106.00M | -135.00M | 0.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.00M | -128.00M | -106.00M | -135.00M | 0.00 |
| EBIT | -96.00M | -134.00M | -114.00M | -142.00M | -8.00M |
| EBITDA | -93.00M | -132.00M | -111.00M | -140.00M | -6.00M |
| EPS Basic | -0.72 | -1.02 | -0.89 | -1.27 | -1.14 |
| Normalized Basic EPS | -0.45 | -0.64 | -0.56 | -0.79 | 0.00 |
| EPS Diluted | -0.72 | -1.02 | -0.89 | -1.27 | -1.14 |
| Normalized Diluted EPS | -0.45 | -0.64 | -0.56 | -0.79 | 0.00 |
| Average Basic Shares Outstanding | 126.10M | 125.40M | 118.50M | 106.50M | 106.10M |
| Average Diluted Shares Outstanding | 126.10M | 125.40M | 118.50M | 106.50M | 106.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |